- Technology and innovation››
- Our products››
- Healthcare associated infections››
- About Bactiguard››
Bactiguard was founded in 2005, however the company's roots go back around 100 years to the 1912, when Gustav Dahlén, the man behind the successful AGA lighthouse system was awarded with the Nobel Prize in Physics.
Gustav Dahlén had a pupil called Axel Bergström, who developed and passed on the technique of coating non-conductive material with a thin layer of metal to his pupil, Billy Södervall. Södervall, the innovator behind the Bactiguard technology, refined the technique and is still actively involved in the company.
DEVELOPING THE CONCEPT
The development of the coating of noble metals that could be applied to medical devices began as far back as the 1970s. The results proved very effective and led to the inventor of Bactiguard, Billy Södervall, applying for patents on the innovation in the USA. The product quickly proved a resounding success.
The company entered into a partnership with US medical device company C.R. Bard. In 1994, the US Food and Drug Administration (FDA) approved the sale of Bardex IC Foley catheters, treated with the Bactiguard infection protection coating. The catheters were launched on the market the following year.
Bactiguard AB was founded in Sweden in 2005 and acquired the business and technology from the previous owner, Adensive Technology. Bactiguard is now taking the technology a step further in preventing and fighting healthcare associated infections, reducing the use of antibiotics and combating the spread of multiresistant bacteria. In 2006, a development and production unit was established in Markaryd, in the south of Sweden, to focus on the further development of the technology.
OWN PRODUCT PORTFOLIO LAUNCHED
In 2006, work started on developing a separate product portfolio and 2008 saw the first delivery of Bactiguard coated latex urinary tract catheters, Bactiguard Infection Protection Foley catheter (BIP Foley catheter). Silicone urinary tract catheters were launched the following year.
In 2013, Bactiguard coated endotracheal tubes (BIP ETT) and central venous catheters (BIP CVC) were launched. A production unit was established that same year in Malaysia, to manufacture urinary tract catheters for the company.
STOCK EXCHANGE LISTING
In June 2014, Bactiguard was floated on the stock exchange. The shares are listed on the NASDAQ OMX Stockholm with the stock symbol Bacti. The aim of the float was to refinance the company and boost continued development and growth.
NEW Integrated HEADquarters
In late 2014, Bactiguard relocated to its new headquarters on Alfred Nobels Allé in Tullinge, south of Stockholm. The new office enabled all parts of the company such as sales and marketing, research, production and product development to come together under the same roof. Another advantage of being based in the new Karolinska Institute Science Park is proximity to research and development at the Karolinska Institute and the Royal Institute of Technology plus healthcare at Karolinska University Hospital which all facilitate closer cooperation.